In the BioHarmony Drug Report Database

"Preview" Icon

Mipomersen

Kynamro (mipomersen) is an oligonucleotide pharmaceutical. Mipomersen was first approved as Kynamro on 2013-01-29. It is used to treat familial combined hyperlipidemia in the USA. Kynamro’s patents are valid until 2027-01-29 (FDA).

 

Trade Name

 

Kynamro
 

Common Name

 

mipomersen
 

ChEMBL ID

 

CHEMBL2219536
 

Indication

 

familial combined hyperlipidemia
 

Drug Class

 

Antisense oligonucleotides

Image (chem structure or protein)

Mipomersen structure rendering